Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more
Icure Pharmaceutical Incorporation (175250) - Total Liabilities
Latest total liabilities as of June 2025: ₩80.55 Billion KRW
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has total liabilities worth ₩80.55 Billion KRW as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Icure Pharmaceutical Incorporation - Total Liabilities Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Icure Pharmaceutical Incorporation Competitors by Total Liabilities
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indointernet Tbk PT
JK:EDGE
|
Indonesia | Rp2.14 Trillion |
|
Global Lithium Resources Ltd
AU:GL1
|
Australia | AU$1.19 Million |
|
Codes Combine Co. Ltd
KQ:047770
|
Korea | ₩23.36 Billion |
|
Derluks Yatirim Holding AS
IS:DERHL
|
Turkey | TL2.50 Billion |
|
NACL Industries Limited
NSE:NACLIND
|
India | ₹10.43 Billion |
|
Geodrill Limited
OTCQX:GEODF
|
USA | $49.18 Million |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
Taiwan | NT$4.79 Billion |
|
Datalex
IR:DLE
|
Ireland | €18.15 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Icure Pharmaceutical Incorporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Icure Pharmaceutical Incorporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual total liabilities of Icure Pharmaceutical Incorporation from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.62 Billion | -31.84% |
| 2023-12-31 | ₩106.54 Billion | -20.76% |
| 2022-12-31 | ₩134.45 Billion | +12.33% |
| 2021-12-31 | ₩119.69 Billion | +44.22% |
| 2020-12-31 | ₩82.99 Billion | -29.82% |
| 2019-12-31 | ₩118.27 Billion | +225.73% |
| 2018-12-31 | ₩36.31 Billion | -0.32% |
| 2017-12-31 | ₩36.43 Billion | +149.76% |
| 2016-12-31 | ₩14.58 Billion | -27.76% |
| 2015-12-31 | ₩20.19 Billion | -- |